TLR4 and hepatocellular carcinoma: To conclude, TLR4 signaling in innate immune cellular populations in HCC TME comprises a potential biomarker and a candidate therapeutic target to prevent HCC, tackle the metastatic process, and reverse drug resistance in DTA-1 treatment.